5198347

PATENT ABSTRACTS

DNA E N C O D I N G P L A S M O D I U M VIVAX AND P L A S M O D I U M

K N O W L E S I DUFFY R E C E P T O R

Louis Miller, John H Adams, David Kaslow, Xiangdon Fang, ,gruobsartS assigned to The United States of America as represented by the Department of Health and Human Services

The present invention relates to DNA segments encoding the Duffy receptor of a Plasmodium parasite, the recombinant DNA and to rccom- binantly produced Duffy receptor. The Duffy receptor can be utilized as a vaccine for humans against malaria.

5198348

E X P R E S S I O N OF E X O G E N O U S P O L Y P E P T I D E S AND

P O L Y P E P T I D E P R O D U C T S I N C L U D I N G H E P A T I T I S B

S U R F A C E ANTIGEN IN YEAST CELLS

Grant Bitter assigned to Amgen Inc

Novel yeast cell transformation vectors are manufactured and employed in securing expres- sion of exogenous polypeptides in yeast cells. Vectors include promoter/regulator DNA sequences of yeast flyceraidehyde-3-phosphate dehydrogenase gene origins. In an illustrative preferred embodiment, novel immunologically active hepatitis B surface antigen (HBsAg) pre- parations are isolated from yeast cells trans- formed with plasmid A.T.C.C. 40053. These HBsAg preparations of yeast origin may be in- corporated into vaccine compositions useful in developing immunological responses protective against infection by hepatitis B virus.

5198349

M E T H O D F O R P R O D U C I N G F A C T O R VIII:C AND A N A L O G S

Randal J Kaufman assigned to Genetics In- stitute Inc

An improved method for producing Factor VIII:c is disclosed. The method involves cul- turing mammalian cells which contain DNA encoding Factor VIII:c and which are capable of expressing Factor VIII:c. In accordance with this invention the cells are cultured in a medium con-

125

raining an effective amount of a Factor VIII:c- stabilizing substance comprising (a) von Willebrand Factor (VWF), (b) a phospholipid or phospholipid mixture, or a mixture of (a) and (b).

5198351

L A C T O S E H Y D R O L Y S I S BY M U T A N T S T R E P T O C O C C U S

T H E R M O P H I L U S

George A Somkuti, Dennis H Steinberg assigned to The United States of America as repl~sented by the Secretary of Agriculture

Mutant strains of Streptococcus thermophilus having defective lactose transport systems having a phenotype, sucS+ and fluS-, lacS- betagai+ are effective for use in processes where the hydrolysis of lactose is sought. Thermost- ability of these strains as well as the beta- galactosidase produced allows lactose hydrolysis prior to and during pasteurization. These or- ganisms provide the food industry with im- proved methods of making reduced lactose dairy products.

5198354

C L O N I N G T H E BAN I R E S T R I C T I O N AND

M O D I F I C A T I O N G E N E S

Geoffrey G Wilson assigned to New England Biolabs Inc

Methods for cloning restriction enzymes and their corresponding modification enzymes by selecting clones resistant to in vitro digestion by the restriction enzyme and subsequent screening to identify those clones containing the restriction gene.

5198360

DNA S E Q U E N C E C O N F E R R I N G A P L A Q U E INHIBITION

P H E N O T Y P E

Margaret M Ballou, Richard Baltz, Margaret A McHenney, Strasbourg, assigned to Eli Lilly and Company

The present invention comprises an -0.8 kb Sac II restriction fragment of phage FP43, which confers the pin phenotype. The present invention allows transduction at high m.o.i, using the phage FP43 high frequency transduction system.